Gilead has given unreal returns in the last couple of years and the company will continue its upward trend due to upcoming HCV catalysts.

In a report published Monday, Oppenheimer analyst David Ferreiro reiterated an Outperform rating and $61.00 price target on Gilead Sciences (NASDAQ: GILD).

Gilead's sofosbuvir will get priority review, which brings it one step closer to upping the bar in hepatitis C treatment.

By Bram de Haas:Gilead Sciences, Inc. (GILD) is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. This is a short article outlining 3 very attractive traits of

Gilead gets FDA priority review status for its game-changing hepatitis C drug.

Monsanto Company (NYSE: MON) soared 2.51% to $104.20 in the pre-market trading. Monsanto declared a Q3 dividend of $0.375 per share. Gilead Sciences (NASDAQ: GILD) moved up 2.02% to $53.96 in the pre-market session.

Drugs from Gilead Sciences and Roche stood out at ASCO this year, while Infinity's drug lagged. Click to view a price quote on GILD. Click to research the Drugs industry.    

June 7 (Reuters) - Biotechnology company Gilead Sciences Inc said the U.S. Food and Drug Administration (FDA) granted priority review to its experimental hepatitis C drug sofosbuvir.

June 7 (Reuters) - Biotechnology company Gilead Sciences Inc said the U.S. Food and Drug Administration (FDA) granted priority review to its experimental hepatitis C drug sofosbuvir.

June 7 (Reuters) - Biotechnology company Gilead Sciences Inc said the U.S. Food and Drug Administration (FDA)granted priority review to its experimental hepatitis C drugsofosbuvir.

ByAlpha Hunter:The US biotechnology industry, which is a speculative growth market, is going up as investors are becoming optimistic about its growth and investing big sums into biotech companies. According to the Financial Times, investors have pour

ByAbba's Aces:Since the beginning of the year all biotech and pharma companies have been making excellent gains, however, the biotech companies such as Celgene (CELG), Gilead (GILD), Biogen Idec (BIIB), and Regeneron (REGN) have been faltering of lat

NEW YORK, June 3 (Reuters) - U.S. stocks early advance lost steam on Monday, with both the S&P 500 and Nasdaq turning negative on declines in Gilead Sciences and Apple.

NEW YORK, June 3 (Reuters) - U.S. stocks early advance lost steam on Monday, with both the S&P 500 and Nasdaq turning negative on declines in Gilead Sciences and Apple.

NEW YORK, June 3 (Reuters) - U.S. stocks early advance lost steam on Monday, with both the S&P 500 and Nasdaq turning negative on declines in Gilead Sciences and Apple.

NEW YORK, June 3 (Reuters) - U.S. stocks early advance loststeam on Monday, with both the S&P 500 and Nasdaq turningnegative on declines in Gilead Sciences and Apple.

Market-trouncing returns could be written in this 4-Star.

ByAbba's Aces:The American Society of Clinical Oncology annual meeting takes place this weekend; 31May13 through 04Jun13 in Chicago. ASCO is a non-profit organization representing physicians of all oncology sub-specialties who would like to give canc

ByCory Renauer:On the fast trackOn May 21 the European Medicines Agency [EMA] delivered some very positive news for Gilead Sciences Inc. (GILD) and its oral hepatitis C drug sofosbuvir. The EMA will provide an accelerated review of Gilead's Marketing

By Peter Geschek:Little noticed Gilead Sciences (GILD), the world's largest maker of HIV drugs, has spent $1.2 billion in the past two years to buy up developers of blood cancer drugs.Treatment for leukemia and other blood cancers is one of the faste

BOSTON (TheStreet) -- Gilead Sciencesand Amarinhighlight the updated list of biotech and pharmaceutical companies with FDA drug approval decisions expected for the remainder of 2013.The next era of hepatitis C therapy could begin on Dec. 6, if FDA ap

Start Time: 09:30End Time: 09:51Gilead Sciences, Inc. (GILD)Company Conference PresentationMay 20, 2013, 09:30 AM ETExecutivesRobin L. Washington - SVP and CFOAnalystsMatthew Roden - UBSPresentationMatthew Roden - UBSGood morning, everyone. My name i

Gilead Sciences, Inc. (Nasdaq: GILD) today announced results from a Phase 2study (Study 101-08) evaluating idelalisib (formerly GS-1101), aninvestigational, targeted, oral inhibitor of PI3K delta, in combination withrituximab for older patients with

FOSTER CITY, Calif. (TheStreet) -- Gilead Sciences'experimental cancer drug idelalisab demonstrated long-lasting tumor shrinkage in more than half of patients with advanced chronic lymphocytic leukemia (CLL). Responses were durable, with disease prog

May 15 (Reuters) - An experimental drug from Gilead Sciences Inc shrank tumors in half of leukemia patients whose cancer had returned, according to an early-stage trial that represents a new foray into oncology by the world's biggest seller of HIV me

May 15 (Reuters) - An experimental drug from Gilead Sciences Inc shrank tumors in half of leukemia patients whose cancer had returned, according to an early-stage trial that represents a new foray into oncology by the world's biggest seller of HIV me

Johnson & Johnson jumps ahead of Gilead Sciences in the race to bring next-generation hepatitis C drugs to market.

The short interest moves in biotech and emerging pharmaceutical companies were mixed in the latter two weeks of April.The number of shares sold short in Dendreon (NASDAQ: DNDN), Gilead Sciences (NASDAQ: GILD), Illumina (NASDAQ:

One of the best performing industries this year has been biotechnology. The S&P biotechnology ETF (XBI) and the Nasdaq Biotech ETF (IBB) have returned 27% and 18% year-to-date, respectively.Those returns are nicely ahead of the 14% return clocked by

May 2 (Reuters) - Gilead Sciences Inc said on Thursday that its quarterly profit rose 63 percent as lower sales of its older HIV drugs were offset by strong sales of new products, but the results fell slightly short of Wall Street estimates.

May 2 (Reuters) - Gilead Sciences Inc said onThursday that its quarterly profit rose 63 percent as lowersales of its older HIV drugs were offset by strong sales of newproducts, but the results fell slightly short of Wall Streetestimates.

May 2 (Reuters) - Gilead Sciences Inc said on Thursday that its quarterly profit rose 63 percent as lower sales of its older HIV drugs were offset by strong sales of new products, but the results fell slightly short of Wall Street estimates.

(Corrects 3rd paragraph to show Complera sales rose 184 percent, not 10 percent; shows that sales of Stribild totaled $92.1 million, with no prior year comparison, not that they rose 184 percent)

May 2 (Reuters) - Gilead Sciences Inc said on Thursday its quarterly profit rose 63 percent as lower sales of the company's older HIV drugs were offset by higher sales of new products and overall revenue rose 11 percent.

(Adds competitive details, analyst comment, updates shares)

May 2 (Reuters) - Gilead Sciences Inc on Thursday said almost all patients taking a fixed-dose combination of two of its experimental hepatitis C drugs appeared to have eliminated the liver virus...

May 2 (Reuters) - Gilead Sciences Inc on Thursdaysaid almost all patients taking a fixed-dose combination of twoof its experimental hepatitis C drugs appeared to haveeliminated the liver virus after either 8 weeks or 12 weeks oftreatment in a small m

May 2 (Reuters) - Gilead Sciences Inc on Thursday said almost all patients taking a fixed-dose combination of two of its experimental hepatitis C drugs appeared to have eliminated the liver virus...

Wall Street is expecting higher profit for Gilead Sciences (GILD) when the company reports its first quarter results on Thursday, May 2, 2013. The consensus estimate is calling for profit of 47 cents a share, a rise from 31 cents per share a year ago

By Toni Clarke WASHINGTON, April 29 (Reuters) - Gilead Sciences Inc said on Monday that U.S. health officials rejected two of its HIV drugs as standalone therapies, citing deficiencies in documentation and validation of certain quality testing proced

By Toni Clarke WASHINGTON, April 29 (Reuters) - Gilead Sciences Inc said on Monday that U.S. health officials rejected two of its HIV drugs as standalone therapies, citing deficiencies in documentation and validation of certain quality testing proced

By Toni ClarkeWASHINGTON, April 29 (Reuters) - Gilead Sciences Inc said on Monday that U.S. health rejected two of its HIVdrugs as standalone therapies, citing deficiencies indocumentation...

AMSTERDAM (TheStreet) -- Hepatitis C drug developers dumped a ton of clinical data on investors this morning as a liver disease meeting gets underway in Amsterdam. An experimental triple combination therapy from Bristol-Myers Squibbappears a bit stro

New hepatitis C data released Tuesday doesn't change the dynamics of the race towards all-oral therapies. Click to view a price quote on GILD. Click to research the Drugs industry.